Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

Blood

Volumn 98, Issue 1, 2001, Pages 29-35

  Rawstron, Andy C ^a,b,c   Kennedy, Ben ^a,b,c   Evans, Paul A S ^a,b,c   Davies, Faith E ^a,b,c   Richards, Stephen J ^a,b,c   Haynes, Andy P ^a,b,c   Russell, Nigel H ^a,b,c   Hale, Geoff ^a,b,c   Morgan, Gareth J ^a,b,c   Jack, Andrew S ^a,b,c   Hillmen, Peter ^a,b,c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD5 ANTIGEN; CD79B ANTIGEN; FLUDARABINE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW DISEASE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REMISSION;

EID: 0035412369     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.1.29     Document Type: Article

References (31)

1. Clavio M, Miglino M, Spriano M, et al. First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur J Haematol. 1998;61:197-203.
2. Magnac C, Sutton L, Cazin B, et al. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther. 1999;41:13-18.
3. Cheson BD. New modalities of therapy in chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 1991;11:167-177.
4. Brugiatelli M, Claisse JF, Lenormand B, et al. Long-term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level [see comments]. Br J Haematol. 1997;97:113-118.
5. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
6. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994;12:748-758.
7. Dyer MJ, Kelsey SM, Mackay HJ, et al. In vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol. 1997;97:669-672.
8. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996;93:151-153.
9. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996;88:2228-2235.
10. Robertson LE, Huh YO, Butler JJ, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis [see comments]. Blood. 1992;80:29-36.
11. Valentin H, Gelin C, Coulombel L, Zoccola D, Morizet J, Bernard A. The distribution of the CDW52 molecule on blood cells and characterization of its involvement in T cell activation. Transplantation. 1992;54:97-104.
12. Hale G, Rye PD, Warford A, Lauder I, Brito-Babapulle A. The glycosylphosphatidylinositolanchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J Reprod Immunol. 1993;23:189-205.
13. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1 H. Lancet. 1988;2:1394-1399.
14. Rebello PR, Hale G, Friend PJ, Cobbold SP, Waldmann H. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 1999;68:1417-1420.
15. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73:1431-1439.
16. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15:1567-1574.
17. Vuillier F, Claisse JF, Vandenvelde C, et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bonemarrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma. 1992;7:195-204.
18. Lenormand B, Bizet M, Fruchart C, et al. Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. Leukemia. 1994;8:1019-1026.
19. Cabezudo E, Matutes E, Ramrattan M, Morilla R, Catovsky D. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia. 1997;11:1909-1914.
20. + hematopoietic progenitors. Blood. 1998;91:2588-2600.
21. Garcia Vela J, Delgado I, Benito L, et al. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999;13:1501-1505.
22. Jennings CD, Foon KA: Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997;90:2863-2892.
23. Owen RG, Johnson RJ,. Rawstron AC, et al. Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol. 1996;49:672-675.
24. Aubin J, Davi F, Nguyen-Salomon F, et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia. 1995;9:471-479.
25. Liang R, Chan V, Chan TK, et al. Detection of immunoglobulin gene rearrangement in lymphoid malignancies of B-cell lineage by seminested polymerase chain reaction gene amplification. Am J Hematol. 1993;43:24-28.
26. Voena C, Ladetto M, Astolfi M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia. 1997;11:1793-1798.
27. Pfitzner T, Engert A, Wittor H, et al. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. Leukemia. 2000;14:754-766.
28. Blythe D, Hand NM, Jackson P, Barrans SL, Bradbury RD, Jack AS. Use of methyl methacrylate resin for embedding bone marrow trephine biopsy specimens. J Clin Pathol. 1997;50:45-49.
29. Lampariello F. On the use of the Kolmogorov-Smimov statistical test for immunofluorescence histogram comparison. Cytometry. 2000;39:179-188.
30. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [see comments]. Blood. 1999;94:1840-1847.
31. Owen RG, Goulden NJ, Oakhill A. et al. Comparison of fluorescent consensus IgH PCR and allele-specific oligonucleotide probing in the detection of minimal residual disease in childhood ALL. Br J Haematol. 1997;97:457-459.